Given the translational relevance of intranasal drug delivery, these findings provide valuable insights into the neuromodulatory role of GAL (1–15) as a potential adjunct to SSRIs in modulating depression-related behavior and its potential implications for mood disorders. This evidence concerns the gene GAL and major depressive disorder.